全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

人血浆脂蛋白相关磷脂酶A2与冠心病的关系
The Relationship between Lipoprotein-Associated Phospholipase A2 and Coronary Heart Disease

DOI: 10.12677/ACM.2020.107188, PP. 1229-1238

Keywords: 人血浆脂蛋白相关磷脂酶A2，冠状动脉粥样硬化性心脏病，Gensini评分
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Coronary Heart Disease (CAD), Gensini Score

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：研究人血浆脂蛋白相关磷脂酶A2 (Lp-PLA2)与冠心病的关系。方法：选取2018年11月至2019年11月期间在青岛大学附属医院心血管内科住院的首次疑诊冠心病并行冠状动脉造影的患者共227例，以冠状动脉造影为金标准，将冠状动脉狭窄≥50%的患者作为冠心病组(160例)，将冠状动脉狭窄<50%的患者作为对照组(67例)。冠心病组又分为单支病变组、双支病变组和三支病变组，同时采用Gensini评分将冠心病组患者分为低分组(≤20分)、中分组(20~≤40)、高分组(>40分)。比较不同组间Lp-PLA2的差异。结果：1) 男性、吸烟、饮酒、血apoA水平降低、肌酐及Lp-PLA2水平是冠心病的危险因素；2) 不同病变支数分组间Lp-PLA2水平不同(P < 0.05)，除单支与双支病变组比较外，各组间均有差异(P < 0.05)；3) 多元回归分析显示：Lp-PLA2是冠心病的独立危险因素；饮酒和LDL是Lp-PLA2的主要相关因素。结论：1) Lp-PLA2是冠心病的独立危险因素且与冠心病严重程度呈正相关；2) 饮酒和LDL是Lp-PLA2的主要相关因素。
Objective: To explore the relationship between lipoprotein-associated phospholipase A2. Methods: Selected the patients who were first suspected coronary atherosclerotic heart disease in the Department of Cardiology of the affiliated Hospital of Qingdao University from November 2018 to November 2019. Totally 227 patients were included in the study, with the standard that coronary artery stenosis ≥50% or not, the patients were divided into coronary artery disease group (160 cases) and control group (67 cases) according to coronary angiography. Besides, patients in coronary heart disease were divided into low score group (≤20), middle score group (20 - ≤40) and high score group (>40) according to Gensini score to compare the level of Lp-PLA2 in different groups. Results: 1) Male, smoking, alcohol, decreased apoA, creatinine and Lp-PLA2 were risk factors for coronary heart disease. 2) The level of Lp-PLA2 was different among different groups (P < 0.05), except single and double branches group; 3) Multiple regression analysis showed that Lp-PLA2 was an independent risk factor for coronary heart disease; drinking and LDL were major influencing factors for Lp-PLA2. Conclusion: 1) Lp-PLA2 is an independent risk factor for coronary heart disease and is positively correlated with the severity of coronary heart disease; 2) Drinking and LDL are main influencing factors for Lp-PLA2.

References

[1]  Libby, P. (2005) Act Local, Act Global: Inflammation and the Multiplicity of “Vulnerable” Coronary Plaques. Journal of the American College of Cardiology, 45, 1600-1602.
https://doi.org/10.1016/j.jacc.2005.02.058
[2]  Jr., G.D., Lloydjones, D.M., Bennett, G., et al. (2014) 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63, 2886.
https://doi.org/10.1016/j.jacc.2014.02.606
[3]  Holst-Albrechtsen, S., Kjaergaard, M., Huynh, A.N., et al. (2013) Can Lipoprotein-Associated Phospholipase A2 Be Used as a Predictor of Long-Term Outcome in Patients with Acute Coronary Syndrome? Current Cardiology Reviews, 9, 310-315.
https://doi.org/10.2174/1573403X09666131202143349
[4]  Huang, F., Wang, K. and Shen, J. (2020) Lipoprotein-Associated Phospholipase A2: The Story Continues. Medicinal Research Reviews, 40, 79-134.
https://doi.org/10.1002/med.21597
[5]  Yang, L., Cong, H.L., Wang, S.F., et al. (2017) AMP-Activated Protein Kinase Mediates the Effects of Lipoprotein-Associated Phospholipase A2 on Endothelial Dysfunction in Atherosclerosis. Experimental and Therapeutic Medicine, 13, 1622-1629.
https://doi.org/10.3892/etm.2017.4142
[6]  Colley, K.J., Wolfert, R.L. and Cobble, M.E. (2011) Lipoprotein Associated Phospholipase A(2): Role in Atherosclerosis and Utility as a Biomarker for Cardiovascular Risk. EPMA Journal, 2, 27-38.
https://doi.org/10.1007/s13167-011-0063-4
[7]  Kleber, M.E., Siekmeier, R., Delgado, G., et al. (2015) C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Smokers and Nonsmokers of the Ludwigshafen Risk and Cardiovascular Health Study. Advances in Experimental Medicine and Biology, 832, 15-23.
https://doi.org/10.1007/5584_2014_6
[8]  Donato, L.J., Meeusen, J.W., Callanan, H., et al. (2016) Advantages of the Lipoprotein-Associated Phospholipase A2 Activity Assay. Clinical Biochemistry, 49, 172-175.
https://doi.org/10.1016/j.clinbiochem.2015.09.002
[9]  Yang, L., Wang, H., Zhang, Y., et al. (2018) The Prognostic Value of Lipoprotein-Associated Phospholipase A2 in the Long-Term Care of Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Clinical and Applied Thrombosis/Hemostasis, 24, 822-827.
https://doi.org/10.1177/1076029617737837
[10]  Greenland, P., Alpert, J.S., Beller, G.A., et al. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 56, e50-e103.
https://doi.org/10.1016/j.jacc.2010.09.001
[11]  郭敏, 闫蕊, 史宏涛, 等. 阿托伐他汀对急性冠脉综合征患者外周血单核细胞源性巨噬细胞脂蛋白相关磷脂酶A2的影响[J]. 中西医结合心脑血管病杂志, 2015, 13(5): 578-580.
[12]  Zheng, D., Cai, A., Xu, R., et al. (2018) Effects and Potential Mechanism of Atorvastatin Treatment on Lp-PLA2 in Rats with Dyslipidemia. Archives of Medical Science, 14, 629-634.
https://doi.org/10.5114/aoms.2017.69494
[13]  范艳平, 李海滨, 谭清武, 等. 人血浆脂蛋白相关磷脂酶A2在冠状动脉粥样硬化中的研究进展[J]. 临床误诊误治, 2016, 29(6): 110-113.
[14]  De Stefano, A., Mannucci, L., Tamburi, F., et al. (2019) Lp-PLA2, a New Biomarker of Vascular Disorders in Metabolic Diseases. International Journal of Immunopathology and Pharmacology, 33, Article ID: 2058738419827154.
https://doi.org/10.1177/2058738419827154
[15]  Cowley, M.J. (2005) Tribute to a Legend in Invasive/Interventional Cardiology Melvin P. Judkins, M.D. (1922-85). Catheterization and Cardiovascular Interventions, 64, 259-261.
https://doi.org/10.1002/ccd.20279
[16]  Gensini, G.G. (1983) A More Meaningful Scoring System for Determining the Severity of Coronary Heart Disease. The American Journal of Cardiology, 51, 606.
https://doi.org/10.1016/S0002-9149(83)80105-2
[17]  Pokharel, Y., Sun, W., Polfus, L.M., et al. (2015) Lipoprotein Associated Phospholipase A2 Activity, Apolipoprotein C3 Loss-of-Function Variants and Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Atherosclerosis, 241, 641-648.
https://doi.org/10.1016/j.atherosclerosis.2015.06.033
[18]  Li, D., Wei, W., Ran, X., et al. (2017) Lipoprotein-Associated Phospholipase A2 and Risks of Coronary Heart Disease and Ischemic Stroke in the General Population: A Systematic Review and Meta-Analysis. Clinica Chimica Acta, 471, 38-45.
https://doi.org/10.1016/j.cca.2017.05.017
[19]  孟心国, 陈魁. 血浆脂蛋白相关磷脂酶A2水平与冠心病冠脉血管病变数量的关系分析[J]. 医学与哲学(B), 2016, 37(6): 37-40.
[20]  罗艳婷, 彭隆, 董睿敏, 等. 脂蛋白相关磷脂酶A_2水平与冠状动脉病变的关系研究[J]. 中华临床医师杂志(电子版), 2015, 9(9): 1520-1524.
[21]  宋温婷, 李秀, 王丹丹, 等. 血浆脂蛋白相关磷脂酶A2对急性心肌梗死患者住院预后的影响[J]. 天津医科大学学报, 2016, 22(2): 107-110.
[22]  Gu, X., Hou, J., Yang, S., et al. (2014) Is Lipoprotein-Associated Phospholipase A2 Activity Correlated with Fibrous-Cap Thickness and Plaque Volume in Patients with Acute Coronary Syndrome? Coronary Artery Disease, 25, 10-15.
https://doi.org/10.1097/MCA.0000000000000041
[23]  武丽娜, 李新华, 柴芳芳, 等. 脂蛋白相关磷脂酶A2与冠状动脉斑块特征相关分析[J]. 中华老年多器官疾病杂志, 2018, 17(4): 287-291.
[24]  Schliefsteiner, C., Hirschmugl, B., Kopp, S., et al. (2017) Maternal Gestational Diabetes Mellitus Increases Placental and Foetal Lipoprotein-Associated Phospholipase A2 Which Might Exert Protective Functions against Oxidative Stress. Scientific Reports, 7, Article No. 12628.
https://doi.org/10.1038/s41598-017-13051-6
[25]  Han, X., Wang, T., Zhang, J., et al. (2015) Apolipoprotein CIII Regulates Lipoprotein-Associated Phospholipase A2 Expression via the MAPK and NFkappaB Pathways. Biology Open, 4, 661-665.
https://doi.org/10.1242/bio.201410900
[26]  Jackisch, L., Kumsaiyai, W., Moore, J.D., et al. (2018) Differential Expression of Lp-PLA2 in Obesity and Type 2 Diabetes and the Influence of Lipids. Diabetologia, 61, 1155-1166.
https://doi.org/10.1007/s00125-018-4558-6
[27]  Silva, I.T., Almeida-Pititto, B. and Ferreira, S.R. (2015) Reassessing Lipid Metabolism and Its Potentialities in the Prediction of Cardiovascular Risk. Archives of Endocrinology and Metabolism, 59, 171-180.
https://doi.org/10.1590/2359-3997000000031
[28]  董乐. 血清脂蛋白磷脂酶A2的浓度水平与急性冠脉综合征的关系[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2018.
[29]  杨丽, 刘寅, 刘婷, 等. 普罗布考联合阿托伐他汀对急性冠脉综合征血脂蛋白相关磷脂酶A2的影响[J]. 天津医药, 2012, 40(2): 156-158.
[30]  Rosenson, R.S. and Hurt-Camejo, E. (2012) Phospholipase A2 Enzymes and the Risk of Atherosclerosis. European Heart Journal, 33, 2899-2909.
https://doi.org/10.1093/eurheartj/ehs148
[31]  Sawada, N. and Liao, J.K. (2014) Rho/Rho-Associated Coiled-Coil Forming Kinase Pathway as Therapeutic Targets for Statins in Atherosclerosis. Antioxidants & Redox Signaling, 20, 1251-1267.
https://doi.org/10.1089/ars.2013.5524
[32]  Ueshima, H., Kadowaki, T., Hisamatsu, T., et al. (2016) Lipoprotein-Associated Phospholipase A2 Is Related to Risk of Subclinical Atherosclerosis But Is Not Supported by Mendelian Randomization Analysis in a General Japanese Population. Atherosclerosis, 246, 141-147.
[33]  Mayer, O.J., Seidlerova, J., Wohlfart, P., et al. (2013) Distribution of Lipoprotein Associated Phospholipase A2 in Czech Population and Its Interaction with Conventional Cardiovascular Risk. Vnitr？ní Lékar？ství, 59, 344-351.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133